Bendamustine

Alkylating Drug — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Bendamustine is an ofp drug in the Alkylating Drug class catalogued in DrugCentral. It was first approved by the FDA in 2008. Its mechanism of action is classified as Alkylating Activity. DrugCentral lists 8 molecular targets, including HDAC6, HDAC2 and HDAC5. Recorded indications include Chronic lymphoid leukemia, disease, Diffuse large B-cell lymphoma refractory, Follicular non-Hodgkin's lymphoma and Indolent B-Cell Lymphoma.

• Approval status: ofp (first approved 2008 by the FDA).
• Drug class: Alkylating Drug.
• Mechanism of action: Alkylating Activity.
• Molecular targets: HDAC6, HDAC2, HDAC5 and HDAC4 (8 listed in DrugCentral).
• Indications: Chronic lymphoid leukemia, disease, Diffuse large B-cell lymphoma refractory, Follicular non-Hodgkin's lymphoma, Indolent B-Cell Lymphoma and Treatment prior to tumor-specific T-cell infusion therapy.
• ATC code: L01AA09 (Nitrogen mustard analogues).
• Molecular formula: C16H21Cl2N3O2; molecular weight 358.27 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (5)

• Chronic lymphoid leukemia, disease
• Diffuse large B-cell lymphoma refractory
• Follicular non-Hodgkin's lymphoma
• Indolent B-Cell Lymphoma
• Treatment prior to tumor-specific T-cell infusion therapy

Off-label uses (1)

• Mantle cell lymphoma

Contraindications (15)

• Acute infectious disease
• Acute nephropathy
• Anemia
• Bone marrow depression
• Breastfeeding (mother)
• Chemotherapy-Induced Hyperuricemia
• Disease of liver
• Fluid volume disorder
• Hepatic failure
• Hyperkalemia
• Kidney disease
• Neutropenic disorder
• Pregnancy, function
• Smokes tobacco daily
• Thrombocytopenic disorder

Mechanism & targets

• Mechanism of action (MoA): Alkylating Activity
• Established pharmacologic class: Alkylating Drug

Molecular targets (8)

Target	Gene	Action	Activity
Histone deacetylase 6	HDAC6	unknown	IC50 8.22
Histone deacetylase 2	HDAC2	unknown	IC50 8.05
Histone deacetylase 5	HDAC5	unknown	IC50 8.00
Histone deacetylase 4	HDAC4	unknown	IC50 8.00
Histone deacetylase 1	HDAC1	unknown	IC50 7.77
Histone deacetylase 3	HDAC3	unknown	IC50 7.60
Histone deacetylase 10	HDAC10	unknown	IC50 7.14
Histone deacetylase 8	HDAC8	unknown	IC50 6.97

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2010-09-27	PMDA	—	SymBio Pharmaceuticals Limited	Yes
2008-03-20	FDA	—	CEPHALON	Yes

ATC classification

ATC code	Therapeutic hierarchy
L01AA09	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › ALKYLATING AGENTS › Nitrogen mustard analogues

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Disease progression	4575.0
Neutropenia	1494.9
Febrile neutropenia	1242.1
Progressive multifocal leukoencephalopathy	1085.4
COVID-19	1073.0
Thrombocytopenia	1009.1
Diffuse large B-cell lymphoma recurrent	980.3
Off label use	967.6
Blood lactate dehydrogenase increased	960.3
Cytomegalovirus infection	931.8
Lymphoma	862.5
Pancytopenia	704.8

Chemical structure

• Molecular formula: C₁₆H₂₁Cl₂N₃O₂
• Molecular weight: 358.27 g/mol
• CAS number: —
• InChIKey: YTKUWDBFDASYHO-UHFFFAOYSA-N
• PubChem CID: 65628

CN1C(CCCC(O)=O)=NC2=CC(=CC=C12)N(CCCl)CCCl

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Bendamustine used for?

DrugCentral lists the following indications for Bendamustine: Chronic lymphoid leukemia, disease, Diffuse large B-cell lymphoma refractory, Follicular non-Hodgkin's lymphoma, Indolent B-Cell Lymphoma and Treatment prior to tumor-specific T-cell infusion therapy.

How does Bendamustine work?

Bendamustine is classified as Alkylating Activity; its molecular targets in DrugCentral include HDAC6, HDAC2, HDAC5 and HDAC4.

When was Bendamustine first approved?

Bendamustine was first approved by the FDA in 2008.

What drug class does Bendamustine belong to?

Bendamustine is in the Alkylating Drug class.

What is the chemical formula of Bendamustine?

Bendamustine has the molecular formula C16H21Cl2N3O2 and a molecular weight of 358.27 g/mol.

Sources

• DrugCentral drug card 302 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1201734 — compound record and bioactivity
• PubChem CID 65628 — chemical identifiers
• DrugBank DB06769 — drug record
• FDA UNII 9266D9P3PQ — substance identity
• DailyMed: FDA labels for Bendamustine — current prescribing information (label search)
• UniProt Q9UBN7 (HDAC6) — target protein
• UniProt Q92769 (HDAC2) — target protein
• UniProt Q9UQL6 (HDAC5) — target protein
• UniProt P56524 (HDAC4) — target protein
• UniProt Q13547 (HDAC1) — target protein
• UniProt O15379 (HDAC3) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.